FDA approval of lecanemab: the real start of widespread amyloid PET use? - the EANM Neuroimaging Committee perspective

Affiliations

• ¹ Department of Nuclear Medicine and Nancyclotep Imaging Platform, Université de Lorraine, CHRU; IADI, INSERM U1254, Nancy, France.
• ² Department of Nuclear Medicine, School of Medicine, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany. igor.yakushev@tum.de.
• ³ Department of Nuclear Medicine, Ludwig Maximilians-University of Munich, Munich, Germany.
• ⁴ Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, the Netherlands.
• ⁵ Nuclear Medicine Unit, Department of Medicine - DIMED, University of Padua, Padua, Italy.
• ⁶ Department of Radiology, Faculty of Medicine and Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela (USC), Campus Vida, Santiago de Compostela, Galicia, Spain.
• ⁷ Institute of Nuclear Medicine, University College London (UCL), London, UK.
• ⁸ APHM, CNRS, Centrale Marseille, Nuclear Medicine Department, Institut Fresnel, Timone Hospital, CERIMED, Aix Marseille Univ, Marseille, France.
• ⁹ Nuclear Medicine Unit, Department of Health Sciences, University of Genoa, Genoa, Italy.
• ¹⁰ Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, the Netherlands.
• ¹¹ Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.
• ¹² Department of Radiology and Nuclear Medicine, Ghent University Hospital, Ghent, Belgium.
• ¹³ Department of Nuclear Medicine, Leipzig University, Leipzig, Germany.